The Motley Fool

Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

While shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have disappointed in the last year, it has not been the same story for a number of its pharmaceutical rivals. In fact, shares in Genus (LSE: GNS) and Dechra (LSE: DPH) have soared in the last 12 months by 35% and 55% respectively, which is a much healthier return than GlaxoSmithKline’s fall of 6%.

Does this mean, then, that Genus and Dechra are better buys that GlaxoSmithKline? Or, is their larger peer now better value for long term investors?

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Margin Of Safety

Suffice to say, it is rare to find a pharmaceutical company that offers a wide margin of safety. That’s even more the case when comparing them to the wider market, since they tend to offer stronger growth in the long run, while their lack of strong correlation to the macroeconomic outlook marks them out as strong defensive plays. So, while all three companies trade at premiums to the FTSE 100, their margins of safety still differ somewhat.

For example, Genus and Dechra currently trade on price to earnings (P/E) ratios of 25.6 and 26.1 respectively, which are significantly higher than the FTSE 100’s P/E ratio of around 16. Certainly, both companies are set to increase their bottom lines at a much faster rate than the wider index, with growth of 16% in the current year and 12% next year pencilled in for Genus. Meanwhile, Dechra is expected to grow its profit by 8% this year and 11% in the following year.

The problem, though, is that these above average growth rates appear to be adequately priced in – especially after their aforementioned share price rises in the last year. As such, there is little margin of safety, which could mean that share price growth is not as impressive as the market is currently anticipating.

GlaxoSmithKline, of course, is lacking significant growth appeal over the next couple of years. In fact, its bottom line is forecast to fall by 4% this year before recovering by 3% next year. So, compared to Genus and Dechra, it is expected to post disappointing results. However, GlaxoSmithKline trades on a much lower rating than its two smaller peers, with it having a P/E ratio of just 16.8. This indicates that if the company is able to deliver on the efficiencies it has planned and which are set to catalyse its bottom line, its valuation has scope to move substantially upwards.

Total Return

Of course, with sales and earnings of pharmaceutical companies being relatively volatile, an income element to total return can be highly worthwhile for investors. In this space, GlaxoSmithKline is the clear winner of the three companies, since it has a dividend yield of 5.3% at the present time. This compares favourably to Genus and Dechra, which have yields of just 1.4% and 1.6% respectively.

And, looking ahead, the total return from GlaxoSmithKline could be higher than that of Genus or Dechra, since it offers a much cheaper share price. And, from next year, it is expected to return to growth, which could act as a catalyst on investor sentiment. So, while Genus and Dechra have massively outperformed GlaxoSmithKline in the last year, the tables could turn for investors taking a long term view.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.